MELANOCORTIN SYSTEM & AROUSAL / COMPARE
Same Family, Very Different Profiles
PT-141 and Melanotan 2 share a chemical ancestor, but diverge sharply on receptor selectivity, clinical evidence, regulatory standing, and safety — and that divergence is the whole story.
The short version
Both PT-141 and Melanotan 2 are cyclic heptapeptides derived from alpha-MSH, and both activate melanocortin receptors in the hypothalamus to produce sexual arousal and erection. But one was deliberately engineered from the other to be more selective — and that selectivity difference explains nearly every way they diverge on the table below. PT-141 (bremelanotide) targets primarily MC4R and received FDA approval for HSDD in premenopausal women in 2019, backed by two large Phase 3 trials [3][5]. Melanotan 2 activates all five melanocortin receptors non-selectively, has never been approved for any indication, completed no Phase 2 or Phase 3 trials, and carries case reports of serious adverse events. Neither compound is presented here with a human dose.
The comparison matrix
| Dimension | PT-141 (bremelanotide) | Melanotan 2 |
|---|---|---|
| Peptide class | Cyclic heptapeptide; selective MC3R/MC4R agonist | Cyclic heptapeptide; non-selective MC1R-MC5R agonist |
| Chemical difference | C-terminal carboxylic acid (-OH) | C-terminal amide (-NH2) |
| Primary studied effects | Sexual desire (HSDD in premenopausal women); arousal; off-label: male erectile function | Skin tanning/pigmentation (MC1R); sexual arousal/erection (MC4R); appetite reduction (MC3R/MC4R) |
| Controlled human evidence | Phase 3 RCTs (n=1,267) + 52-wk extension + fMRI study [2][3][4] | Single 10-person crossover study (1998) [12]; no Phase 2 or Phase 3 trials |
| FDA regulatory status | Approved (HSDD, premenopausal women only) [5] | Not approved for any indication |
| WADA status | S0 non-approved substances (in off-label/research-chemical form) | S0 non-approved substances (prohibited in sport) |
| Pigmentation effect | Low (some MC1R activity at high-frequency dosing) | High (primary MC1R activity) |
| Documented serious AEs | Transient BP rise; nausea; hyperpigmentation with overuse | Renal infarction; rhabdomyolysis; priapism; PRES; eruptive/dysplastic nevi; melanoma cases [10][11] |
| Key caution | Narrow indication; off-label for men and postmenopausal women; BP warning [5] | Non-selective receptor action; no late-phase trials; serious case-report adverse events; unregulated supply |
Selectivity: the defining difference
Receptor selectivity is the thread that runs through every other comparison. MC4R — concentrated in the hypothalamus and limbic system — is responsible for the sexual-desire and arousal effects both compounds share. MC1R — concentrated on skin melanocytes — drives pigmentation. MC3R in mesolimbic circuits modulates appetite.
PT-141 was specifically derived from Melanotan 2 to concentrate activity at MC4R while reducing pigmentation [11]. The result is a compound whose primary documented effect is central arousal signaling, with pigmentation as a secondary concern only at higher-frequency dosing [5]. Melanotan 2 hits all five receptor subtypes simultaneously, which is why a single injection can produce arousal, a skin tan, appetite loss, nausea, and the full range of effects at once — along with less predictable off-target actions at MC2R and MC5R.
Evidence base
The gap in controlled human evidence between the two compounds is large. PT-141 has two pivotal Phase 3 trials in 1,267 women with HSDD [3], a 52-week open-label extension in 684 women [4], and a randomized fMRI mechanistic study in 31 women that directly demonstrates central brain engagement [2]. Melanotan 2 has a single double-blind crossover study in 10 men from 1998 [12] — a landmark finding that produced compelling mechanistic evidence but was never followed by a larger trial for any indication.
The reason for this asymmetry is not that Melanotan 2 stopped working. It is that PT-141 was developed as the more selective and tractable drug candidate, and Melanotan 2 was left behind in development. What circulates as Melanotan 2 in research-use communities is pharmacologically real but entirely outside the scope of any controlled clinical program.
Safety profile
The safety profiles diverge substantially. PT-141's adverse events are well characterized from large trials: nausea (~40% over long-term use), flushing (~20%), headache (~12%), transient blood-pressure increase, and hyperpigmentation with overly frequent dosing [4][5]. These are real, common, and important, but they are quantified and the label specifically addresses them.
Melanotan 2's adverse-event record comes primarily from case reports, because no large controlled trial exists to quantify rates. Published cases document renal infarction with proposed thrombotic mechanism [10], rhabdomyolysis, priapism, posterior reversible encephalopathy syndrome, eruptive new nevi, dysplastic nevi, and melanoma in users [11]. The melanoma risk is not established quantitatively — but multiple case reports document it, and any compound that non-selectively drives melanocyte activity throughout the skin in the presence of UV exposure carries a plausible mechanism for the concern. Additionally, unregulated Melanotan 2 products are repeatedly found to be mislabeled and impure [11], adding contamination risk to pharmacological risk.